Larson Financial Group
TSHA icon

Larson Financial Group’s Taysha Gene Therapies TSHA Stock Holding History

Larson Financial Group’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$2.16K Sell
443
-26
-6% -$150 ﹤0.01% 3204
2026
Q2 		$3.19K Buy
469
+341
+266% +$2.02K ﹤0.01% 2952
2026
Q1 		$572 Buy
+128
New +$595 ﹤0.01% 3292

Other funds holding TSHA

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return
Quantum Private Wealth
Quantum Private Wealth Tampa, Florida $391M AUM 50.76% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Hennion & Walsh Asset Management
Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return
ALPS Advisors
ALPS Advisors Denver, Colorado $21.8B AUM 17.58% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return
Privium Fund Management
Privium Fund Management Amsterdam, Netherlands $516M AUM 18.66% 1-Year Est. Return

Larson Financial Group's TSHA Position: Q3 2026 in Review

Larson Financial Group reduced its Taysha Gene Therapies (TSHA) stake by 5.5% in Q3 2026, selling an estimated $150 and leaving 443 shares worth $2.16K. The position accounts for ﹤0.01% of the portfolio, ranked #3204.

Larson Financial Group first reported a position in TSHA in Q1 2026 and has held it in 3 quarters since. The position peaked at $3.19K in Q2 2026. 64 funds tracked by Wall St. Rank hold TSHA as of Q3 2026.

  • Larson Financial Group held 443 shares of Taysha Gene Therapies worth $2.16K as of Q3 2026.
  • Larson Financial Group sold 26 Taysha Gene Therapies shares in Q3 2026, an estimated $150.
  • Taysha Gene Therapies made up ﹤0.01% of Larson Financial Group's portfolio in Q3 2026, its #3204 holding.
  • Larson Financial Group first reported a position in Taysha Gene Therapies in Q1 2026 and has held it in 3 quarters since.
  • Larson Financial Group's Taysha Gene Therapies position peaked at $3.19K in Q2 2026.
  • 64 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q3 2026.

Based on Larson Financial Group's 13F filing for Q3 2026, filed 5 Nov 2026.